Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma

British Journal of Cancer

Volumn 103, Issue 6, 2010, Pages 837-844

  Santoro, A ^a   Pressiani, T ^a   Citterio, G ^b   Rossoni, G ^b,c   Donadoni, G ^b   Pozzi, F ^b   Rimassa, L ^a   Personeni, N ^a   Bozzarelli, S ^a   Colombi, S ^c   De Braud, F G ^d   Caligaris Cappio, F ^b,e   Lambiase, A ^c   Bordignon, C ^c,e  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c MOLMED S P A   (Italy)

^d EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^e VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

hepatocellular carcinoma; NGR hTNF; vascular targeting agent

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINYLGLYCYLARGININE; ASPARAGINYLGLYCYLARGININE HUMAN TUMOR NECROSIS FACTOR ALPHA FUSION PROTEIN; PEPTIDE DERIVATIVE; SORAFENIB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANGIOGENESIS INHIBITOR; NGR PEPTIDE; OLIGOPEPTIDE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BLOOD PRESSURE; BODY WEIGHT; BRAIN DISEASE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER PAIN; CANCER SURVIVAL; CHILL; CHOLANGITIS; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONFUSION; CONSTIPATION; DEPRESSION; DIARRHEA; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DYSGEUSIA; DYSPEPSIA; DYSPNEA; ESOPHAGUS VARICES BLEEDING; EXTRASYSTOLE; FEMALE; FEVER; FLATULENCE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEADACHE; HEART LEFT BUNDLE BRANCH BLOCK; HEMOPTYSIS; HEMORRHOID; HUMAN; HYPERAMMONEMIA; HYPERBILIRUBINEMIA; HYPERKALEMIA; HYPERURICEMIA; HYPOTENSION; INSOMNIA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LUNG EMBOLISM; LYMPHOCYTOPENIA; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RASH; SIDE EFFECT; SINUS TACHYCARDIA; SYNCOPE; TREATMENT RESPONSE; URIC ACID BLOOD LEVEL; CARCINOMA, HEPATOCELLULAR; LIVER NEOPLASMS; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; VASCULARIZATION;

ADULT; AGED; ANGIOGENESIS INHIBITORS; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; OLIGOPEPTIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77956438555     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605858     Document Type: Article

References (27)

1. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, Taylor J, Moscovici M, Saltz LB (2006) Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24: 4293
2. Arap W, Pasqualini R, Ruoslahti E (1998) Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279: 377-380
3. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B (1975) An endotoxin-induced serum factor that causes necrosis of tumours. Proc Natl Acad Sci 72: 3666-3670
4. Cheng AL, Kang YK, Chen Z, et Tsao CJ, Qin S, Kim JS, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WJ, Pan H, Burok K, Zou J, Voliotis D, Guan Z (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10: 25-34
5. Corti A, Ponzoni M (2004) Tumor vascular targeting with tumor necrosis factor alpha and chemotherapeutic drugs. Ann NY Acad Sci 1028: 104-112
6. Curnis F, Arrigoni G, Sacchi A, Fischetti L, Arap W, Pasqualini R, Corti A (2002a) Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells. Cancer Res 62: 867-874
7. Curnis F, Sacchi A, Borgna L, Magni F, Gasparri A, Corti A (2000) Enhancement of tumor necrosis factor alpha antitumor immuno-therapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat Biotechnol 18: 1185-1190
8. Curnis F, Sacchi A, Corti A (2002b) Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. J Clin Invest 110: 475-482
9. Faivre SJ, Raymond E, Douillard J, Boucher E, Lim HJ, Kim JS, Lanzalone S, Lechuga MJ, Sherman L, Cheng A (2007) Assessment of safety and drug-induced tumor necrosis with sunitinib in patients with unresectable hepatocellular carcinoma (HCC). J Clin Oncol 25: 3546
10. Ferrero E, Scabini S, Magni E, Foglieni C, Belloni D, Colombo B, Curnis F, Villa A, Ferrero ME, Corti A (2004) Chromogranin A protects vessels against tumor necrosis factor alpha-induced vascular leakage. FASEB J 20: 20
11. Gregorc V, Citterio C, Vitali G, Spreafico A, Scifo P, Borri A, Donadoni G, Rossoni G, Corti C, Caligaris-Cappio F, Del Maschio A, Esposito A, De Cobelli F, Dell'Acqua F, Troysi A, Bruzzi P, Lambiase A, Bordignon C (2010) Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours. Eur J Cancer 46: 198-206
12. Gregorc V, Santoro A, Bennicelli E, Punt CJA, Citterio G, Timmer-Bonte JNH, Caligaris-Cappio F, Lambiase A, Bordignon C, van Herpen CML (2009) Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours. Br J Cancer 101: 219-224
13. Gregorc V, Spreafico A, Floriani I, Colombo B, Ludovini V, Pistola L, Bellezza G, Viganò MG, Villa E, Corti A (2007) Prognostic value of circulating chromogranin A and soluble tumor necrosis factor receptors in advanced nonsmall cell lung cancer. Cancer 110: 845-853
14. Greten TF, Korangy F, Manns MP, Malek NP (2009) Molecular therapy for the treatment of hepatocellular carcinoma. Br J Cancer 100: 19-23
15. Lejeune FJ, Lienard D, Matter M, Ruegg C (2006) Efficiency of recombinant human TNF in human cancer therapy. Cancer immun 6: 6-23
16. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J, Gores GJ (2008a) Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100: 698-711
17. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, Cosme de Oliveira A, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J (2008b) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390
18. O'Dwyer PJ, Giantonio BJ, Levy DE, Kauh JS, Fitzgerald DB, Benson AB (2006) Gefitinib in advanced unresectable hepatocellular carcinoma: results from the Eastern Cooperative Oncology Group's Study E1203. J Clin Oncol 24: 4143
19. Philip PA, Mahoney MR, Allmer C, Thomas J, Pitot HC, Kim G, Donehower RC, Fitch T, Picus J, Erlichman C (2005) Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 23: 6657-6663 (Pubitemid 46190260)
20. Rangel R, Sun Y, Guzman-Rojas L, Ozawa MG, Sun J, Giordano RJ, Van Pelt CS, Tinkey PT, Behringer RR, Sidman RL, Arap W, Pasqualini R (2007) Impaired angiogenesis in aminopeptidase N-null mice. Proc Natl Acad Sci USA 104: 4588-4593
21. Sacchi A, Gasparri A, Gallo-Stampino C, Toma S, Curnis F, Corti A (2006) Synergistic antitumor activity of cisplatin, paclitaxel, and gemcitabine with tumor vasculature-targeted tumor necrosis factor-alpha. Clin Cancer Res 12: 175-182
22. Shaked Y, Ciarrocchi A, Franco M, Lee CR, Man S, Cheung AM, Hicklin DJ, Chaplin D, Stuart Foster F, Benezra R, Kerbel RS (2006) Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 22: 1785-1787
23. Siegel AB, Cohen EI, Ocean A, Lehrer D, Goldenberg A, Knox JJ, Chen H, Clark-Garvey S, Weinberg A, Mandeli J, Christos P, Mazumdar M, Popa E, Brown Jr RS, Rafii S, Schwartz JD (2008) Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocel-lular carcinoma. J Clin Oncol 26: 2992-2998
24. Thomas MB, Chadha R, Glover K, Wang X, Morris J, Brown T, Rashid A, Dancey J, Abbruzzese JL (2007) Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 110: 1059-1067
25. Van Laarhoven HWM, Fiedler W, Desar IME, van Asten JJA, Sandrine Marréaud S, Lacombe D, Govaerts AS, Bogaerts J, Lasch P, Timmer-Bonte JNH, Lambiase A, Bordignon C, Punt CJA, Heerschap A, van Herpen CML (2010) Phase I clinical and magnetic resonance imaging study of the vascular agent NGR-hTNF in patients with advanced cancers (European Organization for Research and Treatment of Cancer Study 16041). Clin Cancer Res 16: 1315-1323
26. Zhu AX, Sahani DV, di Tomaso E, Duda D, Sindhwani V, Yoon SS, Blaszkowsky LS, Clark JW, Ryan DP, Jain RK (2007a) A phase II study of sunitinib in patients with advanced hepatocellular carcinoma. J Clin Oncol 25: 4637
27. Zhu AX, Stuart K, Blaszkowsky LS, Muzikansky A, Reitberg DP, Clark JW, Enzinger PC, Bhargava P, Meyerhardt JA, Horgan K, Fuchs CS, Ryan DP (2007b) Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer 110: 581-589